Why the study?
Does enzyme replacement therapy by plasma transfusion improve lipid and apoprotein profiles in patients with familial LCAT deficiency?
Does enzyme replacement therapy by plasma transfusion improve lipid and apoprotein profiles in patients with familial LCAT deficiency?
Plasma transfusion in familial LCAT deficiency improves triglyceride-rich lipoprotein composition and apo E levels, suggesting LCAT plays a physiological role in triglyceride metabolism.
May improve TG-rich lipoprotein profiles in LCAT deficiency; hypothesis-generating for therapy and LCAT's role in triglyceride metabolism.
The siblings presented here are the third family found in Japan with familial LCAT deficiency. Their post-heparin plasma lipoprotein lipase and hepatic triglyceride lipase activities were measured selectively by an immunochemical method. Plasma triglyceride levels were elevated, and post-heparin plasma lipoprotein lipase was decreased only in a patient with nephropathy, while hepatic triglyceride lipase activities were within reference limits in both patients. The plasma concentrations of apo A-I, apo A-II, and apo B were reduced in both patients. On the other hand, the plasma concentration of apo E was markedly increased. Enzyme replacement therapy by plasma transfusion in the propositus resulted in marked improvement of deranged compositions of triglyceride-rich lipoproteins. Also, improvement of the plasma apo E concentration was demonstrated, while the improvement of post-heparin lipase did not occur. These results suggest that LCAT may play an important physiological role in triglyceride metabolism as well as in cholesterol metabolism.
No takes yet. Share an insight, caveat, or question.
Murayama et al. (1984) studied this question.